Literature DB >> 21256824

Biodegradable chitosan particles induce chemokine release and negligible arginase-1 activity compared to IL-4 in murine bone marrow-derived macrophages.

Jessica Guzmán-Morales1, Marianne B Ariganello, Ines Hammami, Marc Thibault, Mario Jolicoeur, Caroline D Hoemann.   

Abstract

Alternatively activated macrophages have been implicated in the therapeutic activity of biodegradable chitosan on wound healing, however, the mechanisms of phenotypic differentiation are still unclear.In vitro, macrophages stimulated with high doses of chitosan (≥ 500 μg/mL) were reported to produce low-level markers associated with alternative activation (arginase-1) as well as classical activation (nitric oxide), and to undergo apoptosis. In this study, we tested the hypothesis that 40 kDa biodegradable chitosan (5-500 μg/mL) is sufficient to polarize mouse bone marrow-derived macrophages (BMDM) in vitro to an alternatively activated phenotype. Control cultures were stimulated with IL-4 (alternative activation), IFN-γ/LPS (classical activation), 1 μm diameter latex beads (phagocytosis), or left untreated. After 48 h of in vitro exposure, BMDM phagocytosed fluorescent chitosan particles or latex beads, and remained viable and metabolically active, although some cells detached with increasing chitosan and latex bead dosage. Arginase-1 was over 100-fold more strongly induced by IL-4 than by chitosan, which induced only sporadic and weak arginase-1 activity over untreated BMDM, and no nitric oxide. IFN-γ/LPS stimulated nitric oxide production and arginase-1 activity and high concentrations of inflammatory cytokines (IL-6, IL-1β, TNF-α, MIP-1α/MIP-1β), while latex beads stimulated nitric oxide and not arginase-1 activity. Chitosan or latex bead exposure, but not IL-4, tended to promote the release of several chemokines (MIP-1α/β, GM-CSF, RANTES, IL-1β), while all treatments promoted MCP-1 release. These data show that chitosan phagocytosis is not sufficient to polarize BMDM to the alternative or the classical pathway, suggesting that biodegradable chitosan elicits alternatively activated macrophages in vivo through indirect mechanisms.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21256824     DOI: 10.1016/j.bbrc.2011.01.063

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis.

Authors:  Maowei Wang; Yan Yue; Chunsheng Dong; Xiaoyun Li; Wei Xu; Sidong Xiong
Journal:  Clin Vaccine Immunol       Date:  2013-09-11

2.  In vitro efficacy of polysaccharide-based nanoparticles containing disease-modifying antirheumatic drugs.

Authors:  Nan Zhang; Patricia R Wardwell; Rebecca A Bader
Journal:  Pharm Res       Date:  2014-03-05       Impact factor: 4.200

3.  The absence of MyD88 has no effect on the induction of alternatively activated macrophage during Fasciola hepatica infection.

Authors:  HongLin Luo; Weiyi Huang; Dongying Wang; Haoju Wang; Kui Nie
Journal:  BMC Immunol       Date:  2011-11-11       Impact factor: 3.615

4.  Chitosan immunomodulatory properties: perspectives on the impact of structural properties and dosage.

Authors:  David Fong; Caroline D Hoemann
Journal:  Future Sci OA       Date:  2017-09-14

Review 5.  Chitosans for delivery of nucleic acids.

Authors:  Michael D Buschmann; Abderrazzak Merzouki; Marc Lavertu; Marc Thibault; Myriam Jean; Vincent Darras
Journal:  Adv Drug Deliv Rev       Date:  2013-07-18       Impact factor: 15.470

6.  Chitosan rate of uptake in HEK293 cells is influenced by soluble versus microparticle state and enhanced by serum-induced cell metabolism and lactate-based media acidification.

Authors:  Caroline D Hoemann; Jessica Guzmán-Morales; Nicolas Tran-Khanh; Geneviève Lavallée; Mario Jolicoeur; Marc Lavertu
Journal:  Molecules       Date:  2013-01-15       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.